The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice.
SGLT2 抑制劑對 ob/ob 小鼠的代謝表現型和脂肪組織及肝臟中 FGF-21 表達的影響較不明顯。
BMC Endocr Disord 2025-03-10
Exploring the Protective Effects of Schisandrin A and Schisandrin B Against Diabetic Cardiomyopathy With a Possible Mechanism Involving Complement Inhibition.
探討 Schisandrin A 和 Schisandrin B 對糖尿病心肌病的保護作用及其可能涉及的補體抑制機制。
Phytother Res 2025-03-09
這項研究探討了五味子果實中的木脂素Schisandrin A (SchA)和Schisandrin B (SchB)對1型糖尿病小鼠心肌病的保護作用。結果顯示，這兩種化合物能顯著降低血糖、改善胰臟功能，並增強心臟功能，減少心室肥大和心肌纖維化。此外，SchA和SchB還展現抗炎和抗氧化特性，可能透過抑制補體反應來保護心臟。這項研究顯示它們在未來治療糖尿病心肌病方面的潛力。
相關文章PubMedDOI推理
The SGLT2 inhibitor dapagliflozin suppresses endothelial cell pyroptosis mediated by the NF-κB/NLRP3 pathway through downregulation of CTSB.
SGLT2 抑制劑 dapagliflozin 透過下調 CTSB 抑制由 NF-κB/NLRP3 通路介導的內皮細胞焦亡。
Biochem Pharmacol 2025-03-09
Fasting is not always good: perioperative fasting leads to pronounced ketone body production in patients treated with SGLT2 inhibitors: a case report.
禁食並不總是有益的：圍手術期禁食導致接受 SGLT2 抑制劑治療的患者產生顯著的酮體生成：一例報告。
Korean J Fam Med 2025-03-09
Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits.
心臟科、內分泌科及初級護理就診的2型糖尿病患者中SGLT2抑制劑和GLP-1受體激動劑的處方模式。
Mayo Clin Proc 2025-03-09
Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses.
透析患者中使用 GLP-1 受體激動劑對於 2 型糖尿病的潛在益處：需要全面的藥物動力學和透析分析。
Cardiovasc Diabetol 2025-03-08
SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis.
SGLT2 抑制劑與 2 型糖尿病患者腎結石風險：一項隊列研究和統合分析。
Diabetes Res Clin Pract 2025-03-08
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
探討減重藥物與甲狀腺癌之間的關聯：檢視 FDA 不良事件報告系統資料庫。
Endocrinol Diabetes Metab 2025-03-08